CytoDyn Inc. (CYDY)

CytoDyn Income Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2026	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021
Revenue	-	-	-	-	0.27	-
Cost of Revenue	-	-	-	20.63	73.54	5.03
Gross Profit	-	-	-	-20.63	-73.28	-5.03
Selling, General & Admin	7	7.26	10.82	17.14	44.3	34.32
Research & Development	14.41	-16.92	7.24	2.63	27.04	53.4
Amortization of Goodwill & Intangibles	-	-	-	0.13	-	-
Operating Expenses	21.42	-9.66	18.06	19.94	72.13	89.52
Operating Income	-21.42	9.66	-18.06	-40.58	-145.4	-94.55
Interest Expense	-2.97	-4.86	-8.89	-15.51	-24.18	-22.11
Interest & Investment Income	0.29	0.57	0.22	-	-	-
Other Non Operating Income (Expenses)	-1.95	-0.85	-3.06	-18.43	-	-
EBT Excluding Unusual Items	-26.05	4.52	-29.79	-74.51	-169.59	-116.66
Asset Writedown	-	-	-	-	-	-10.05
Legal Settlements	-12.75	-	-	-	-3.85	-10.63
Other Unusual Items	-	-0.77	-20.05	-5.31	-37.38	-39.13
Pretax Income	-38.79	3.75	-49.84	-79.82	-210.82	-176.47
Net Income	-38.79	3.75	-49.84	-79.82	-210.82	-176.47
Preferred Dividends & Other Adjustments	1.48	1.48	1.48	6.91	1.63	1.69
Net Income to Common	-40.28	2.26	-51.32	-86.74	-212.45	-178.15
Shares Outstanding (Basic)	1,257	1,206	970	837	677	588
Shares Outstanding (Diluted)	1,257	1,243	970	837	677	588
Shares Change (YoY)	9.37%	28.20%	15.90%	23.58%	15.20%	39.54%
EPS (Basic)	-0.03	0.00	-0.05	-0.10	-0.31	-0.30
EPS (Diluted)	-0.04	0.00	-0.05	-0.10	-0.31	-0.30
Free Cash Flow	-17.98	-8.77	-10.98	-25.11	-77.72	-117.7
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.03	-0.12	-0.20
Operating Margin	-	-	-	-	-54663.16%	-
Profit Margin	-	-	-	-	-79867.67%	-
Free Cash Flow Margin	-	-	-	-	-29219.17%	-
EBITDA	-21.4	9.68	-18.03	-40.4	-144.62	-92.75
D&A For EBITDA	0.02	0.02	0.03	0.18	0.78	1.8
EBIT	-21.42	9.66	-18.06	-40.58	-145.4	-94.55

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.